Zafirlukast, like other LTRAs, operates by inhibiting the immune program. As a result of its motion on inflammatory cells inside the lungs, zafirlukast reduces the production of inflammatory mediators which might be implicated inside the pathogenesis of bronchial asthma. Zafirlukast inhibits bron